Novartis and Ratio Therapeutics Ink $745M Radiopharmaceutical Deal

Deal Value:
Novartis has signed a deal worth up to $745 million with Ratio Therapeutics for rights to a radiopharmaceutical candidate aimed at treating cancer35.

Partnership:
The partnership focuses on advancing a radiopharmaceutical program, expanding Novartis's portfolio in this area35.

Radiopharmaceuticals:
The deal highlights the growing interest in radiopharmaceuticals, a class of drugs that use radioactive isotopes to target and destroy cancer cells35.

Cancer Treatment:
The agreement underscores Novartis's commitment to developing innovative cancer treatments, leveraging Ratio Therapeutics' expertise in radiopharmaceuticals35.

Biotech Collaboration:
The deal is part of a broader trend in biotech collaborations, where major pharmaceutical companies like Novartis partner with smaller biotechs to access cutting-edge technologies and therapies35.

Sources:

3. https://www.fiercebiotech.com/biotech/novartis-ratio-sign-radiopharmaceutical-pact-tune-745m-biobucks

5. https://cafepharma.com/content/novartis-ratio-sign-radiopharmaceutical-pact-tune-745m-biobucks